Arformoterol Tartrate Inhalation Solution
Product Images NDC 76204-026

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate Inhalation Solution (NDC 76204-026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ritedose Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Rdp-arf-30ct-singles (Rdp Arf 30ct Singles Carton)

Rdp-arf-30ct-singles (Rdp Arf 30ct Singles Carton)
Packaging label for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL sterile unit-dose vials. The label indicates the product is for oral inhalation only and is supplied in a 30 x 2 mL carton. It is manufactured by Ritedose Pharmaceuticals, LLC. Storage instructions specify to keep refrigerated or store at room temperature for up to 6 weeks. The label includes a barcode and customer service contact information.*
FDA Label Image

Rdp-arf-60ct-singles (Rdp Arf 60ct Singles Carton)

Rdp-arf-60ct-singles (Rdp Arf 60ct Singles Carton)
The image shows a flat layout of the Arformoterol Tartrate Inhalation Solution carton label by Ritedose Pharmaceuticals, LLC. The product is 15 mcg per 2 mL, indicated for oral inhalation only. The label includes storage instructions to keep refrigerated or store at room temperature for up to 6 weeks. The carton is for 60 sterile unit-dose vials of 2 mL each.*
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
Chemical structure of Arformoterol Tartrate, the active ingredient in Arformoterol Tartrate Inhalation Solution 15 ug/2mL by Ritedose Pharmaceuticals, LLC. The image shows the molecular structure including the arformoterol moiety and tartrate component.*
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
A line graph showing mean change from baseline FEV1 (L) over 12 hours postdose. Two lines represent treatment groups: placebo (with near zero change) and 15 mcg Arformoterol Tartrate Inhalation Solution BID (showing an increase peaking around 0.25 L). The x-axis is labeled Hours Postdose and the y-axis Mean Change from Baseline FEV1.*
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
A line graph illustrating mean change from baseline FEV1 (L) over 12 hours postdose comparing placebo and 15 mcg Arformoterol Tartrate Inhalation Solution BID. The x-axis shows hours postdose from 0 to 12, and the y-axis shows mean change in FEV1 ranging from -0.10 to 0.30 liters. The 15 mcg Arformoterol group shows a higher increase in mean FEV1 compared to placebo throughout the 12-hour period.*
FDA Label Image

Figure-04 (Figure 04)

Figure-04 (Figure 04)
Instructional image showing hands demonstrating how to open an ampule by snapping its neck, indicated by an arrow curving to the side. The ampule contains a liquid solution for inhalation.*
FDA Label Image

Figure-05 (Figure 05)

Figure-05 (Figure 05)
An instructional diagram showing a hand inserting a small vial or ampule of solution into a respiratory inhalation device's reservoir. The device and vial are depicted in black and white, illustrating the preparation step for using the Arformoterol Tartrate Inhalation Solution inhaler.*
FDA Label Image

Figure-06 (Figure 06)

Figure-06 (Figure 06)
An instructional diagram showing the components of a respiratory inhalation device labeled as 'MOUTHPIECE.' The image highlights the mouthpiece part detached from the main body of the inhaler, illustrating how the mouthpiece fits onto the device.*
FDA Label Image

Figure-07 (Figure 07)

Figure-07 (Figure 07)
An instructional illustration showing a face mask connected to an inhalation device. The diagram emphasizes the proper placement of the face mask for respiratory administration of the inhalation solution.*
FDA Label Image

Figure 08 (Figure 08)

Figure 08 (Figure 08)
An illustration depicting part of a compressor device used with respiratory inhalation solutions. The image shows a rectangular compressor unit labeled "COMPRESSOR" with a control knob and a display. There is a tube labeled "TUBING" connected to the compressor, likely illustrating setup for inhalation therapy with attached tubing.*
FDA Label Image

Figure-09 (Figure 09)

Figure-09 (Figure 09)
An instructional illustration showing a person holding a medication inhaler device near their mouth, demonstrating the proper technique for administering inhalation solution by respiratory route.*
FDA Label Image

Rdp-01 (Rdp 01)

Rdp-01 (Rdp 01)
FDA Label Image

Rdp-02 (Rdp 02)

Rdp-02 (Rdp 02)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.